These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

98 related items for PubMed ID: 16647466

  • 1. Antiproliferative and overadditive effects of everolimus and mycophenolate mofetil in pancreas and lung cancer cells in vitro.
    Stracke S, Ramudo L, Keller F, Henne-Bruns D, Mayer JM.
    Transplant Proc; 2006 Apr; 38(3):766-70. PubMed ID: 16647466
    [Abstract] [Full Text] [Related]

  • 2. Everolimus and mycophenolate mofetil sensitize human pancreatic cancer cells to gemcitabine in vitro: a novel adjunct to standard chemotherapy?
    Tuncyurek P, Mayer JM, Klug F, Dillmann S, Henne-Bruns D, Keller F, Stracke S.
    Eur Surg Res; 2007 Apr; 39(6):380-7. PubMed ID: 17700025
    [Abstract] [Full Text] [Related]

  • 3. Antiproliferative and overadditive effects of rapamycin and FTY720 in pancreatic cancer cells in vitro.
    Shen Y, Wang X, Xia W, Wang C, Cai M, Xie H, Zhou L, Zheng S.
    Transplant Proc; 2008 Jun; 40(5):1727-33. PubMed ID: 18589181
    [Abstract] [Full Text] [Related]

  • 4. Everolimus and mycophenolate mofetil are potent inhibitors of fibroblast proliferation after lung transplantation.
    Azzola A, Havryk A, Chhajed P, Hostettler K, Black J, Johnson P, Roth M, Glanville A, Tamm M.
    Transplantation; 2004 Jan 27; 77(2):275-80. PubMed ID: 14742993
    [Abstract] [Full Text] [Related]

  • 5. Antiproliferative profile of sirolimus and mycophenolate mofetil: impact of the SI/MPL ratio.
    Voisard R, Geçgüner L, Baur R, Herter T, Hombach V.
    Int J Cardiol; 2005 Jul 20; 102(3):435-42. PubMed ID: 16004888
    [Abstract] [Full Text] [Related]

  • 6. Effects of mycophenolate mofetil on key pattern of coronary restenosis: a cascade of in vitro and ex vivo models.
    Voisard R, Viola S, Kaspar V, Weber CM, von Müller L, Baur R, Gastrock-Balitsch I, Hombach V.
    BMC Cardiovasc Disord; 2005 May 12; 5(1):9. PubMed ID: 15890069
    [Abstract] [Full Text] [Related]

  • 7. [Toxic effect of immunosuppression agent Everolimus on insuloma cells and pancreatic islets of SD rat].
    Jin X, Cong C, Yuan Y, Mai G, Wei LL, Chen YN, Cheng JQ, Lu YR.
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2010 Jan 12; 41(1):68-72. PubMed ID: 20369473
    [Abstract] [Full Text] [Related]

  • 8. Calcineurin inhibitors in bronchiolitis obliterans syndrome following stem cell transplantation.
    Hostettler KE, Halter JP, Gerull S, Lardinois D, Savic S, Roth M, Tamm M.
    Eur Respir J; 2014 Jan 12; 43(1):221-32. PubMed ID: 23645405
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Everolimus in combination with mycophenolate mofetil as pre- and post-transplantation immunosuppression after nonmyeloablative hematopoietic stem cell transplantation in canine littermates.
    Machka C, Lange S, Werner J, Wacke R, Killian D, Knueppel A, Knuebel G, Vogel H, Lindner I, Roolf C, Murua Escobar H, Junghanss C.
    Biol Blood Marrow Transplant; 2014 Sep 12; 20(9):1301-6. PubMed ID: 24923538
    [Abstract] [Full Text] [Related]

  • 11. Cyclosporine A, FK-506, 40-0-[2-hydroxyethyl]rapamycin and mycophenolate mofetil inhibit proliferation of human intrahepatic biliary epithelial cells in vitro.
    Liu C, Schreiter T, Frilling A, Dahmen U, Broelsch CE, Gerken G, Treichel U.
    World J Gastroenterol; 2005 Dec 28; 11(48):7602-5. PubMed ID: 16437685
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Mycophenolate mofetil inhibits rat and human mesangial cell proliferation by guanosine depletion.
    Hauser IA, Renders L, Radeke HH, Sterzel RB, Goppelt-Struebe M.
    Nephrol Dial Transplant; 1999 Jan 28; 14(1):58-63. PubMed ID: 10052478
    [Abstract] [Full Text] [Related]

  • 14. Combination of everolimus and tacrolimus in kidney transplant patients with intolerance to mycophenolate mofetil/mycophenolic acid.
    Balda S, Inza A, Odriozola N, Zárraga S, García-Erauskin G, Lampreabe I.
    Transplant Proc; 2009 Jan 28; 41(6):2095-8. PubMed ID: 19715841
    [Abstract] [Full Text] [Related]

  • 15. A 1-year randomized controlled study of everolimus versus mycophenolate mofetil with reduced-dose cyclosporine in maintenance heart transplant recipients.
    Bara C, Dengler T, Hack MA, Ladenburger S, Lehmkuhl HB.
    Transplant Proc; 2013 Jan 28; 45(6):2387-92. PubMed ID: 23953553
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Cardiac allograft vasculopathy by intravascular ultrasound in heart transplant patients: substudy from the Everolimus versus mycophenolate mofetil randomized, multicenter trial.
    Kobashigawa JA, Pauly DF, Starling RC, Eisen H, Ross H, Wang SS, Cantin B, Hill JA, Lopez P, Dong G, Nicholls SJ, A2310 IVUS Substudy Investigators.
    JACC Heart Fail; 2013 Oct 28; 1(5):389-99. PubMed ID: 24621971
    [Abstract] [Full Text] [Related]

  • 19. Longitudinal growth on an everolimus- versus an MMF-based steroid-free immunosuppressive regimen in paediatric renal transplant recipients.
    Billing H, Burmeister G, Plotnicki L, Ahlenstiel T, Fichtner A, Sander A, Höcker B, Tönshoff B, Pape L.
    Transpl Int; 2013 Sep 28; 26(9):903-9. PubMed ID: 23865768
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.